本文選題：糖尿病腎病 + SD大鼠　； 參考：《南京中醫(yī)藥大學》2016年碩士論文

【摘要】：目的：糖尿病腎病(Diabetic Nephropathy, DN)是糖尿病患者微血管并發(fā)癥之一,發(fā)病機制及相關(guān)治療是世界醫(yī)學面臨的一大難題,研究DN的道路任重道遠。本實驗通過研究肝素結(jié)合表皮生長因子樣生長因子(heparin-binding epidermal growth factor-like growth factor, HB-EGF)在DN模型大鼠血清和腎臟組織中的表達以及黃葵素的干預作用,對黃葵素治療DN的可能機制作一個初步的探討。方法：首先從60只SPF級雄性的SD大鼠中隨機抽取10只,設(shè)為空白組,其余50只則為造模組�？瞻捉M的大鼠給予普通飼料飼養(yǎng),造模組所有大鼠均采用高脂飲食聯(lián)合小劑量STZ腹腔注射的方法建立DN大鼠模型。再將DN造模成功的大鼠隨機分成模型組、陽性對照組以及黃葵素高、中、低劑量組,每組10只。陽性對照組的大鼠予厄貝沙坦溶液灌胃給藥,黃葵素高、中、低劑量組的大鼠分別給予高、中、低濃度黃葵素混懸液灌胃給藥；空白組、模型組的大鼠都采用雙蒸水灌胃。給藥12周后收集標本,靜脈血用于測血糖；大鼠尿液用于U-mAlb/Cr的測定；血清用ELASA法行HB-EGF定量檢測；腎臟組織運用熒光定量RT-PCR法檢測HB-EGF總mRNA的表達。結(jié)果：與空白組相比,模型組、陽性對照組以及黃葵素高、中、低劑量組大鼠的血糖、尿微量白蛋白/肌酐、血清HB-EGF濃度水平、腎組織中HB-EGF分子mRNA的表達量均明顯升高,且具有統(tǒng)計學差異。陽性對照組、黃葵素高劑量組大鼠血糖、尿微量白蛋白／肌酐、血清HB-EGF濃度水平、腎組織中HB-EGF分子mRNA的表達量均低于模型組大鼠,差異有統(tǒng)計學意義。黃葵素中、低劑量組大鼠血糖、尿微量白蛋白／肌酐、血清HB-EGF濃度水平、腎組織中HB-EGF分子mRNA的表達量與模型組大鼠無顯著差異。結(jié)論：DN模型大鼠存在腎臟損害的同時伴有HB-EGF表達的增多；運用黃葵素對這類大鼠進行干預后,各組大鼠血糖、尿蛋白均得到一定程度的控制,同時大鼠血清和腎臟組織中]HB-EGF的表達也相應的減少,并且存在一定的量效關(guān)系,因此,黃葵素治療DN可能與通過抑制HB-EGF的表達有關(guān)。
[Abstract]:Objective: diabetic nephropathy (DN) is one of the microvascular complications in diabetic patients. The purpose of this study was to investigate the expression of heparin-binding epidermal growth factor-like growth factor (HB-EGF) in serum and kidney of DN model rats and the intervention effect of flavitin on the expression of heparin-like growth factor-like growth factor (HB-EGF) in serum and kidney of DN rats. To explore the possible mechanism of sunflower in the treatment of DN. Methods: ten SPF male SD rats were randomly selected as blank group and the other 50 rats as model group. The rats in the blank group were fed with common diet and all the rats in the model group were fed with high fat diet combined with small dose STZ intraperitoneal injection to establish DN rat model. The rats were randomly divided into the model group, the positive control group and the high, middle and low dosage groups with 10 rats in each group. The rats in the positive control group were given irbesartan solution by gavage, and the rats in the high, middle and low dose groups were given the high, middle and low concentration of flavitin suspension respectively, while in the blank group, the rats in the model group were fed with double-steamed water respectively. After 12 weeks of administration, blood samples were collected and blood was used to measure blood glucose; rat urine was used to determine U-mAlb/Cr; serum ELASA was used for quantitative detection of HB-EGF; and renal tissue was used to detect the expression of total mRNA of HB-EGF by fluorescence quantitative RT-PCR method. Results: compared with the blank group, the levels of blood glucose, urinary microalbumin / creatinine, serum HB-EGF concentration, and the expression of HB-EGF molecule mRNA in kidney were significantly increased in the model group, positive control group and high, middle and low dose groups. And there is statistical difference. In the positive control group, the levels of blood glucose, urinary albumin / creatinine, serum HB-EGF concentration, and the expression of HB-EGF molecule mRNA in renal tissue were significantly lower in the high-dose group than in the model group. There was no significant difference in the levels of blood glucose, urinary albumin / creatinine, serum HB-EGF concentration and the expression of HB-EGF molecule mRNA between the low dose group and the model group. Conclusion there is renal damage and increase of HB-EGF expression in the rats with 1: DN model, and the blood glucose and urine protein in each group are controlled to some extent after the intervention of horseradine on these rats, and the results are as follows: (1) the blood glucose and urine protein of the rats in each group were controlled to a certain extent. At the same time, the expression of HB-EGF in serum and kidney of rats was also decreased, and there was a dose-effect relationship. Therefore, the treatment of DN with flavidin may be related to the inhibition of HB-EGF expression.
【學位授予單位】：南京中醫(yī)藥大學
【學位級別】：碩士
【學位授予年份】：2016
【分類號】：R259

【相似文獻】

相關(guān)期刊論文 前5條

1 伍參榮;蔡銳;李珊;申可佳;賈本真;李芳榮;;黃葵素對結(jié)核分枝桿菌的抑殺作用研究[J];湖南中醫(yī)藥大學學報;2011年11期

2 梁寧;覃夢嵐;;黃葵的顯微鑒別研究[J];中國民族醫(yī)藥雜志;2009年11期

3 劉嘉;劉漢清;張明;張平;;黃葵總黃酮緩釋片釋放度影響因素研究[J];醫(yī)藥導報;2010年09期

4 李培源;蘇煒;霍麗妮;鄧超澄;劉良銓;盧澄生;;黃葵籽揮發(fā)油化學成分及其抗氧化活性研究[J];時珍國醫(yī)國藥;2012年03期

5 ;[J];;年期

相關(guān)會議論文 前1條

1 劉漢清;劉嘉;張明;張平;;黃葵總黃酮緩釋片釋放度影響因素考察研究[A];2009全國中藥創(chuàng)新與研究論壇學術(shù)論文集[C];2009年

相關(guān)碩士學位論文 前3條

1 錢曉翠;黃葵素對糖尿病腎病大鼠中HB-EGF表達的影響[D];南京中醫(yī)藥大學;2016年

2 張明;黃葵緩釋片研制及體外釋藥研究[D];南京中醫(yī)藥大學;2009年

3 趙娜;5/6腎切除大鼠LPA水平及其膜受體Edg-7的表達及黃葵腎保護作用的研究[D];吉林大學;2008年

，

本文編號：1967684